Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03663647
Other study ID # ADMIRE
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 8, 2018
Est. completion date April 27, 2019

Study information

Verified date September 2021
Source MelanomaPRO, Russia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective chart review Study of patients with BRAF V600 positive advanced (unresectable or metastatic) melanoma, who were treated with targeted therapy in routine clinical practice in Russian Federation


Description:

This study is an observational multicentral retrospective chart review study in patients with BRAF V600 positive advanced (unresectable or metastatic) cutaneous melanoma, who have treated by BRAF inhibitors (BRAFi) or MEK inhibitors (MEKi) in routine clinical practice in Russia. 300 patients will be included in the study. The study does not aim to prove any formal hypothesis and does not imply any intervention in standard medical care, and all medical events recorded during the study have already occurred. The data sources of this study will be medical records, patients' charts and other related medical documentation that allows to fully follow the course of the disease and collect all the necessary information according to Protocol. For identification of molecular genetic markers that cause resistance and sensitivity to targeted therapy, an analysis of tumor tissue will be provided in the laboratory of biological microchips "Institute of Molecular Biology. V.A. Engelhardt" of the Russian Academy of Sciences. The analyzed materials will be paraffin blocks with samples of tumor tissue of only patients with primary resistance to targeted therapy (inhibitors BRAF / +/- MEK inhibitor). In the course of the study, the Contract Research Organization (CRO) "Crocus Medical B.V." will conduct periodic monitoring visits to ensure that the data collected are accurate and credible. Regular monitoring visits include Source Data Verification (SDV) in accordance with the monitoring plan, monitoring compliance with the research procedures, as well as the proper and timely maintenance of the main clinical study documents, including the reporting provided for by the rules of good clinical practice, the legislation of the Russian Federation and Standard Operating Procedures (SOPs) of the CRO. The investigators will be responsible for the collection and provision of all clinical and laboratory data, as well as safety data, that are entered in electronic Case Report Forms (e-CRF), and must ensure data authenticity and compliance with the primary documentation. Before hard database lock, the database will be inspected in order to reveal missing and suspicious data. The queries will be generated to correct or fill-in such data. In case the data failed to refine, their will be considered as missing, no data-imputation methods are planned. One of the efficacy endpoints of the study is defined as overall survival which represents the time-to-event data, these data will be analyzed with Kaplan-Meyer method and Cox regression. Time to event will be defined as a number of days passed from start of treatment until any-cause death. Patients alive until the end of study will be right-censored by the end-of-study day or by the day of preliminary withdrawal. Based on Kaplan-Meyer curves the following parameters would be accessed: median survival, one- and two-year survival. The Cox regression will include the following covariates: age, sex, baseline therapy, presence of metastasis in brain, baseline level of lactic dehydrogenase (LDH), number of tissues with metastasis, time from the beginning of the target therapy, etc. Additional covariates could be also accessed when necessary. The hazard ratio (HR) along with 95% confidence interval will be evaluated for each covariate. Analyses of categorical efficacy endpoints (number of patients taken different therapies, objective response rate, number of patients with molecular genetics alterations) will be performed with chi-square criterion or Fisher's exact test in case of any expected frequencies below 5. In addition, the logistic regression could be build based on the above mentioned covariates. The odds ratio (OR) along with 95% confidence interval will be evaluated for each covariate. The progression-free survival (PFS) will be analyzed analogously as described above for the overall survival data. Time to event will be defined as a number of days passed from treatment start until either any-cause death or documented disease progression whichever occurs first. Patients without event will be right-censored by the end-of-study day or by the day of preliminary withdrawal. Based on Kaplan-Meyer curves the following parameters would be accessed for all the patients as well as for the subgroups of baseline therapy (target therapy, immunochemistry, chemotherapy): 6-, 12-, 18- and 24-months progression-free survival. In addition, the PFS will be analyzed for the patients treated with BRAFi as a monotherapy with successive inclusion of the MEKi. Time to response and duration of response data will be analyzed similarly. Time to response will be defined as a number of days passed from treatment start until first documented response to the therapy. Non-responders will be right-censored by the end-of-study day or by the day of preliminary withdrawal. This analyses will be conducted for all the patients as well as for the subgroups of baseline therapy (target therapy, immunochemistry, chemotherapy). Analyses of the duration of response will be performed only among the responders. Duration of the response will be defined as a number of days passed from the first documented response until either any-cause death or documented disease progression whichever occurs first. Patients responding until the study end will be right censored by the end-of-study day or by the day of preliminary withdrawal. The data on duration of the therapy will be presented with descriptive statistics for each therapy line. Adverse events (AE) and Serious Adverse Events (SAE) will be coded according to MedDRA. Each AE/SAE will be summarized with counts and frequencies. The data on AE will be tabulated by System Organ Classes (SOC) and presented with indication their preferred terms (PT) by baseline therapy and severity. When necessary, the comparison of frequencies of AEs/SAEs between subgroups will performed with chi-square criterion or Fisher's exact test in case of any expected frequencies below 5.


Recruitment information / eligibility

Status Completed
Enrollment 382
Est. completion date April 27, 2019
Est. primary completion date April 27, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Histological confirmed cutaneous melanoma - BRAF V600 mutation - Treated by at least one therapy line including BRAFi / MEKi Exclusion Criteria: - No data of targeted therapy usage and treatment outcomes (data of evaluation of effect and data of objective examination)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Russian Federation Moscow Regional Oncologic Dispensary Balashikha
Russian Federation Belgorod Oncologic Dispensary Belgorod
Russian Federation Republican Clinical Oncologic Dispensary Cheboksary
Russian Federation Kaluga Regional Clinical Oncologic Dispensary Kaluga
Russian Federation N.N. Blokhin National Medical Research Centre of Oncology Moscow
Russian Federation Clinical Oncologic Dispensary Omsk
Russian Federation City Clinical Oncologic Dispensary Saint Petersburg
Russian Federation N.N. Petrov National Medical Research Centre of Oncology Saint Petersburg
Russian Federation St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncology) Saint Petersburg
Russian Federation Tula Regional Oncologic Dispensary Tula
Russian Federation Voronezh Regional Clinical Oncologic Dispensary Voronezh

Sponsors (2)

Lead Sponsor Collaborator
MelanomaPRO, Russia Crocus Medical B.V.

Country where clinical trial is conducted

Russian Federation, 

References & Publications (1)

Orlova KV, Ledin EV, Zhukova NV, Orlova RV, Karabina EV, Volkonskiy MV, Stroyakovskiy DL, Yurchenkov AN, Protsenko SA, Novik AV, Vorotilina LV, Moiseenko FV, Chang VL, Kazmin AI, Tkachenko SA, Gamaunov SV, Naskhletashvili DR, Samoylenko IV, Vikhrova AS, U — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Frequency of occurrence of any progression types on different treatments The rate of progression and type according to TNM classification for melanoma 4 years
Primary Approach to therapy in patients with metastatic or unresectable BRAF mutant melanoma Percentages of patients who were treated by targeted, immunotherapy and chemotherapy or other therapy types of treatment usage in each line of treatment 4 years
Secondary Overall survival (OS) of patients with stage III (unresectable) and stage IV BRAF V600-positive cutaneous melanoma The median OS of patients with unresectable advanced BRAF mutant melanoma during targeted therapy 5 years
Secondary Overall survival (OS) of patients with stage III (unresectable) and stage IV BRAF V600-positive cutaneous melanoma 2 year OS rate of patients with unresectable advanced BRAF mutant melanoma during targeted therapy 5 years
Secondary The response rate during therapy in patients with unresectable advanced BRAF mutant melanoma The ORR by subgroup of patients with unresectable advanced BRAF mutant melanoma during targeted therapy 4 years
Secondary Disease control rate (DCR) in patients with unresectable advanced BRAF mutant melanoma The DCR by subgroup of patients with unresectable advanced BRAF mutant melanoma 4 years
Secondary Progression free survival (PFS) of patients with stage III (unresectable) and stage IV BRAF V600-positive cutaneous melanoma The median PFS and 24 months PFS rate of patients with unresectable advanced BRAF mutant melanoma during targeted therapy 4 years
Secondary The incidence of adverse events during targeted therapy The rate of all grade and grade 3-5 adverse events and the rate of discontinuation of study drug(s) due to adverse events. 5 years
Secondary The PFS in patients with advanced BRAF mutant melanoma during targeted therapy by type of BRAF mutation The PFS rate according to the mutation BRAF subtype 4 years
Secondary The OS in patients with advanced BRAF mutant melanoma during targeted therapy by type of BRAF mutation The OS rate according to the mutation BRAF subtype 4 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04074096 - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis Phase 2
Active, not recruiting NCT05103891 - Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations Phase 1
Recruiting NCT05501912 - A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors Phase 1
Recruiting NCT05510895 - Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer Phase 2
Recruiting NCT04741997 - Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma Early Phase 1
Completed NCT04775095 - BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation
Recruiting NCT05546905 - A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
Active, not recruiting NCT03514901 - To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. Phase 2
Terminated NCT04190628 - Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors Phase 1
Terminated NCT03430947 - Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases Phase 2
Withdrawn NCT04759846 - Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma Phase 1
Recruiting NCT04911998 - A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients
Not yet recruiting NCT06054191 - Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations Phase 2
Not yet recruiting NCT05275374 - XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation Phase 1/Phase 2
Completed NCT05810740 - Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations Phase 1
Recruiting NCT05800340 - Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC Phase 2
Recruiting NCT05786924 - A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Phase 1